WO2007109275A2 - Combinaison de paclitaxel - Google Patents

Combinaison de paclitaxel Download PDF

Info

Publication number
WO2007109275A2
WO2007109275A2 PCT/US2007/006920 US2007006920W WO2007109275A2 WO 2007109275 A2 WO2007109275 A2 WO 2007109275A2 US 2007006920 W US2007006920 W US 2007006920W WO 2007109275 A2 WO2007109275 A2 WO 2007109275A2
Authority
WO
WIPO (PCT)
Prior art keywords
paclitaxel
oxy
phenyl
diamine
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/006920
Other languages
English (en)
Other versions
WO2007109275A3 (fr
Inventor
Ajay Bhargava
Christopher Carter
Michael Brands
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Bayer Healthcare LLC
Original Assignee
Bayer Pharmaceuticals Corp
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp, Bayer Healthcare LLC filed Critical Bayer Pharmaceuticals Corp
Priority to CA002646971A priority Critical patent/CA2646971A1/fr
Priority to EP07753541A priority patent/EP2001477A4/fr
Priority to JP2009501514A priority patent/JP2009530386A/ja
Publication of WO2007109275A2 publication Critical patent/WO2007109275A2/fr
Anticipated expiration legal-status Critical
Publication of WO2007109275A3 publication Critical patent/WO2007109275A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • This invention relates to a novel combination of compounds and processes for its preparation, methods of treating diseases, particularly cancer, comprising administering said combination, and methods of making said pharmaceutical composition for the treatment or prevention of disorders, particularly cancer.
  • Cancer is a disease resulting from an abnormal growth of tissue. Certain cancers have the potential to invade into local tissues and also metastasize to distant organs. This disease can develop in a wide variety of different organs, tissues and cell types. Therefore, the term “cancer” refers to a collection of over a thousand different diseases.
  • Cancer treatments are of two major types, either curative or palliative.
  • the main curative therapies for cancer are surgery and radiation. These options are generally successful only if the cancer is found at an early localized stage. Once the disease has progressed to locally advanced cancer or metastatic cancer, these therapies are less effective and the goal of therapy aims at symptom palliation and maintaining good quality of life.
  • the most prevalent treatment protocols in either treatment mode involve a combination of surgery, radiation therapy and/or chemotherapy.
  • Cytotoxic drugs are used in the treatment of cancer, either as a curative treatment or with the aim of prolonging life or palliating symptoms. Cytotoxics may be combined with radiotherapy and/or surgery, as neoadjuvant treatment (initial chemotherapy aimed at shrinking the tumor, thereby rendering local therapy such as surgery and radiation more effective) or as adjuvant chemotherapy (used in conjunction or after surgery and/or localized therapy). Combinations of different drugs are frequently more effective than single drugs: they may provide an advantage in certain tumors of enhanced response, reduced development of drug resistance and/or increased survival. It is for these reasons that the use of combined cytotoxic regimens in the treatment of many cancers is very common.
  • Taxol (Paclitaxel), chemical name benzenepr ⁇ panoic acid, beta ⁇ -(benzoylarnino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)- 12-(benzoyloxy)-2a,3 ,4,4a,S ,6,9, 10, 11 , 12, 12a, 12b-dodecahydro- 4,ll-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,l l-methano-lH-cyclodeca(3,4)benz(l,2- b)oxet-9-ylester,(2aR-(2aalpha,4beta,4abeta,6beta,9aIpha(alphaR*,betaS*), 1
  • the present invention provides a combination of 6-(6- ammopyridin-3-yl)-N 4 - ⁇ 4-[(2-methylpyridin-4-yl)oxy]phenyl ⁇ pyrimidine-2,4-diamine:
  • Combination refers to the result or product of combining two or more individual units, ingredients or compounds.
  • combination refers to a spatial relationship. These units, ingredients or compounds can remain unchanged in the combination, or they can to a lesser or greater extent react or interact. Also, they can be physically brought and blended together to form one mixture, or they can be brought together into a container without blending.
  • Combination also refers to the result or product of combining said ingredients, if they are further processed or treated after having been combined.
  • an example of a combination is cookie dough, which consists of several ingredients being mixed together. If the cookie dough in above example is baked and covered with frosting, it still remains a combination.
  • combination refers to the product of combining two or more pharmaceutical ingredients, such as pharmaceutically active compounds, and also refers to this product if it is further processed and packaged, such as two pharmaceutically active compounds being brought together to form a mixture, the mixture then being pressed into a tablet, the tablet then subsequently being coated and packaged. The tablet still remains a combination.
  • combination refers to a temporal relationship, i.e. two or more acts are performed simultaneously or in temporal proximity. Acts are performed simultaneously, when they are done at the same point in time or in overlapping time periods. For example, a tv set simultaneusly transmits sound and picture and thus transmits a combination of the two.
  • Two or more acts can also be perfomed in temporal proximity, i.e. after one another, to form a combination. What counts as temporal proximity is dependent on the totality of circumstances; one indicator being that the acts are being performed to achieve a certain purpose; another that the acts are being performed shortly after one another on a timescale relevant for the observed system.
  • a sequence of chess moves is often referred to as a combination, while the moves are being done one after the other with the opponent making his intermittent moves. They are done with the purpose of eventually defeating the opponent.
  • the actual time elapsed between the acts performed in a combination can thus be irrelevant.
  • combination refers to a drug regimen, wherein a patient is administered two or more drugs to treat a disease.
  • the exact circumstances of administering the drug can vary, but would still represent a combination.
  • a physician might consider to administer two antibacterial drugs to the patient, where administering these drugs within an interval of several minutes to hours or even a few days would be considered a combination.
  • administration of two drugs within an interval of days or weeks could be considered a combination, as long as it is done by the physician as parts of a treatment, that is with the intention of treating the respective disease.
  • To combine refers to the act of bringing two or more individual units, ingredients or compounds into close relationship. They can be brought together in a spatial sense, e.g. combined into one mixture, also referred to as intermixing or blending. For example, to prepare a cookie dough several ingredients are being mixed together. This can happen by filling them all into a container and mixing them, or by placing one ingredient in a container and subsequently, while mixing, adding the remaining ingredients. In the example described above, one can bring two or more pharmaceutical ingredients together, form a mixture, press the mixture into a tablet, then subsequently coat and package the tablet. By bringing the ingredients together one combines them within the meaning of the present invention.
  • 'to combine' refers to a temporal relationship, i.e. two or more acts are performed simultaneously or in temporal proximity ⁇ as discussed above under Combination.
  • the present invention provides a process for preparing a combination of 6-(6-aminopyridin-3-yl)-N 4 - ⁇ 4-[(2-methylpyridin-4- yl)oxy]phenyl ⁇ pyrimidine-2,4-diamine with Paclitaxel, comprising combining 6-(6- aminopyridin-3-yl)-N 4 - ⁇ 4-[(2-methylpyridin-4-yl)oxy]phenyl ⁇ pyrimidine-2,4-diamine and Paclitaxel.
  • this process can be performed using techniques known to the person skilled in the pharmaceutical art.
  • the present invention provides a pharmaceutical composition comprising a combination of 6-(6-aminopyridin-3-yl)-N 4 - ⁇ 4-[(2- methylpyridin-4-yl)oxy]phenyl ⁇ pyrimidine-2,4-diamine with Paclitaxel; and a process for preparing a pharmaceutical composition comprising a combination of 6-(6-aminopyridin- 3-yl)-N 4 - ⁇ 4-[(2-methylpyridin-4-yl)oxy]phenyl ⁇ pyrimidine-2,4-diamine with Paclitaxel, comprising combining 6-(6-aminopyridin-3-yl)-N 4 - ⁇ 4-[(2-methy ⁇ p yridin-4- yl)oxy]phenyl ⁇ pyrimidine-2,4-diamine and Paclitaxel. and converting them into a suitable pharmaceutical composition.
  • this process can be performed using techniques known to the person skilled in the pharmaceutical art.
  • the present invention provides a pharmaceutical composition comprising a combination of 6-(6-aminopyridin-3-yl)-N 4 - ⁇ 4-[(2- methylpyridin-4-yl)oxy]phenyl ⁇ pyrimidine-2,4-diamine with Paclitaxel and a pharmaceutically acceptable carrier; and a process for preparing a pharmaceutical composition comprising a combination of 6-(6-aminopyridin-3-yl)-N 4 - ⁇ 4-[(2- methylpyridin-4-yl)oxy]phenyl ⁇ pyrimidine-2,4-diamine with Paclitaxel and a pharmaceutically acceptable carrier, comprising combining 6-(6-aminopyridin-3-yl)-N 4 -
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a combination of 6-(6-aminopyridin-3-yl)-N 4 - ⁇ 4-[(2- methylpyridin-4-yl)oxy]phenyl ⁇ pyrimidine-2,4-diamine with Paclitaxel and a pharmaceutically acceptable carrier, wherein said pharmaceutical composition is suitable for parenteral administration.
  • Parenteral administration can be carried out by avoiding an absorption step (e.g. by intravenous, intraarterial, intracardiac intraspinal or intralumbar administration) or by including absorption (e.g. by intramuscular, subcutaneous, intracutaneous or intraperitoneal administration).
  • Suitable parenteral administration forms are for example injection and infusion formulations in the form of solutions, suspensions, emulsions, lyophilisates and sterile powders.
  • Such parenteral pharmaceutical compositions are described in Part 8, Chapter 84 of Remington's Pharmaceutical Sciences, 18 lh ed. 1990, Mack Publishing Group, Enolo.
  • the invention relates to intravenous (i.v.) application of the active compounds, e.g. as bolus injection (that is as single dose, e.g. per syringe), infusion over a short period of time (e.g. for up to one hour) or infusion over a long period of time (e.g. for more than one hour).
  • the application can also be done by intermittent dosing.
  • the applied volume can vary dependent on the conditions and usually is 0.5 to 30, or 1 to 20 ml for bolus injection, 25 to 500, or 50 to 250 ml for infusion over a short period of time and 50 to 1000, or 100 to 500 ml for infusion over a long period of time.
  • the present invention provides a pharmaceutical composition suitable for intraveneous administration over a short or long period of time.
  • the application forms should be sterile and free of pyrogens. They can be based on aqueous solvents or mixtures of aqueous and organic solvents. Examples are ethanol, polyethyleneglycol (PEG) 300 or 400, aqueous solutions containing cyclodextrins or emulsifiers, such as lecithin, Pluronic F68®, Solutoi HSl 5® or Cremophor®. Aqueous solutions are preferred. For intravenous application the solutions are generally isotonic and euhydric, for example with a pH of 3 to 11, 6 to 8 or about 7.4.
  • Glass or plastic containers can be employed as packaging for i.v.-solutions, e.g. rubber seal vials. They can contain liquid volumes of 1 to 1000, or 5 to 50 ml. The solution can directly be withdrawn from the vial to be applied to the patient. For this purpose, it can be advantageous to provide the active compound in solid form (e.g. as lyophilisate) and dissolve by adding the solvent to the vial directly before administration.
  • i.v.-solutions e.g. rubber seal vials. They can contain liquid volumes of 1 to 1000, or 5 to 50 ml.
  • the solution can directly be withdrawn from the vial to be applied to the patient.
  • Solutions for infusion can advantageously be packaged in containers made from glass or plastic, for example bottles or collapsible containers such as bags. They can contain liquid volumes of 1 to 1000, or 50 to 500 ml.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising 6-(6-aminopyridin-3-yl)-N 4 - ⁇ 4-[(2-methylpyridin-4- yl)oxy] ⁇ henyl ⁇ pyrimidine-2,4-diamine, Paclitaxel, purified Cremophor EL and dehydrated ethyl alcohol.
  • the present invention provides a packaged pharmaceutical composition, comprising a container comprising a combination of 6-(6- aminopyridin-3-yl)-N 4 - ⁇ 4-[(2-methylpyridin-4-yl)oxy]phenyl ⁇ pvrimidine-2,4-diamine with Paclitaxel and a pharmaceutically acceptable carrier and instructions for using the pharmaceutical composition to treat a disease in a patient; and.a packaged pharmaceutical composition, wherein the container is a bottle or collabsible bag.
  • the present invention provides a kit-of-parts, comprising a plurality of containers comprising 6-(6-aminopyridin-3 -Vl)-N 4 - ⁇ 4-[(2- methylpyridin-4-yl)oxy]phenyl ⁇ pyrimidine-2,4-diamine and Paclitaxel or both, optionally further comprising instructions for using the kit-of-parts to treat a disease in a patient.
  • the present invention provides a process for preparing a combination of 6-(6-aminopyridin-3-yl)-N 4 - ⁇ 4-[(2-rnethylpyridin-4- yl)oxy]phenyl ⁇ pyrimidine-2,4-diamine with Paclitaxel, comprising combining 6-(6- aminopyridin-3-yl)-N 4 - ⁇ 4-[(2-methylpyridin-4-yl)oxy]phenyl ⁇ pyrimidine-2,4-diamine with Paclitaxel, purified Cremophor EL and dehydrated ethyl alcohol.
  • the present invention provides a method for treating a disorder, comprising administering to a patient a pharmaceutically effective amount of a combination of 6-(6-aminopyridin-3-yl)-N 4 - ⁇ 4-[(2-methylpyridin-4- yl)oxy]phenyl ⁇ pyrimidine-2,4-diamine with Paclitaxel; or a method for treating a disorder, comprising administering to a patient a pharmaceutically effective amount of a pharmaceutical composition comprising a combination of 6-(6-aminopyridin-3-yl)-N 4 - ⁇ 4- [(2-methylpyridin-4-yl)oxy]phenyl ⁇ pyrimidine-2,4-diamine with Paclitaxel and a pharmaceutically acceptable carrier; or said method, wherein the is suitable for intraveneous administration; or wherein the intraveneous administration is intraveneous administration over a short or long period of time; or said pharmaceutical composition suitable for intraveneous administration; or a method for treating a disorder
  • the present invention provides said method for treating a disorder, wherein said disorder is cancer. In yet another embodiment, the present invention provides a method for treating cancer, wherein said cancer is small cell lung cancer.
  • the present invention provides a method for treating a disorder, comprising administering to a patient a pharmaceutically effective amount of a combination of 6-(6-aminopyridin-3-yl)-N 4 - ⁇ 4-[(2-methylpyridin-4- yl)oxy]phenyl ⁇ pyrimidine-2,4-diamine with Paclitaxel, wherein 6-(6-aminopyridin-3-yl)- N 4 - ⁇ 4-[(2-methylpyridin-4-yl)oxy]phenyl ⁇ pyrimidine-2,4-diamine and Paclitaxel are administered simultaneously or in temporal proximity, such as within 24 hours.
  • the present invention provides a method for treating a disorder, comprising administering to a patient a pharmaceutically effective amount of a combination of 6-(6-aminopyridin-3-yl)-N 4 - ⁇ 4-[(2-methyl ⁇ yridin-4- yl)oxy]phenyl ⁇ pyrimidine-2,4-diamine with Paclitaxel, wherein 6-(6-aminopyridin-3-yl)- N 4 - ⁇ 4-[(2-methyl ⁇ yridin-4-yl)oxy]phenyl ⁇ pyrimidine-2,4-diamine together with 6mg Paclitaxel, 527 mg of purified Cremophor® EL (polyoxyethylated castor oil) and 49.7% (v/v) dehydrated alcohol per ml are diluted in 0.9% Sodium Chloride Injection, USP; 5% Dextrose Injection, USP; 5% Dextrose and 0.9% Sodium Chloride Injection, USP 5 or 5% Dext
  • the present invention provides a method for treating a disorder, comprising administering to a patient a pharmaceutically effective amount of a combination of 6-(6-aminopyridin-3-yl)-N 4 - ⁇ 4-[(2-methylpyridin-4- yl)oxy]phenyI ⁇ pyrimidine-2,4-diamine with Paclitaxel, wherein less than the maximum tolerated dose is administered or patient weight loss is minimized.
  • Paclitaxel is commercially available or can be prepared similarly to known processes.
  • 6-(6-amino ⁇ yridin-3-yl)-N 4 - ⁇ 4-[(2-methylpyridin-4-yl)oxy]phenyl ⁇ pyrimidine- 2,4-diamine is a dry powder with a color ranging from white to ivory or light yellow and can be prepared as follows:
  • Step 1 Preparation of ⁇ 4-r(2-Methylpyridin-4-yl)oxy1 phenyl) amine
  • Step 2 Preparation of 6-chloro-N 4 -f4- ⁇ r2-methylpyridin-4-yl1oxy)phenyl)pyrimidine-2,4- diamine
  • Triethylamine (20 mL) was then added and the mixture was stir for additional 10 min at 90 0 C. Water was then added in excess until cloudiness persisted at temperature. This was cooled to about 5 0 C and precipitate formed were collected by suction filtration, washed with water and dried in vacuum oven at 40 0 C to afford desired product (50 g, 64%) as light tan solid.
  • Step 3 Preparation of . ⁇ -C ⁇ -aminopyridin-S-v ⁇ -lS ⁇ - ⁇ -fr ⁇ -methylpyridin- ⁇ - vDoxyiphenyl > pyrimidine-2,4-diamine
  • the resulting mixture was degassed for 10 min before it was heated at 80 0 C overnight.
  • the resulting mixture was cooled to rt before it was concentrated under vacuo and dissolved in EtOAc.
  • the resulting mixture was washed with water and brine and the organic layer was dried over Na 2 SO 4 .
  • the utility of the compounds of the present invention can be illustrated, for example, by their activity in vitro in the in vitro tumor cellular proliferation assay described below.
  • the link between activity in tumor cell proliferation assays in vitro and anti-tumor activity in the clinical setting has been very well established in the art.
  • taxol Silvestrini et al. Stem Cells 1993, 11(6), 528-35
  • taxotere Bissery et al. Anti Cancer Drugs 1995, 6(3), 339
  • topoisomerase inhibitors Edelman et al. Cancer Chemother. Pharmacol. 1996, 37(5), 385-93 were demonstrated with the use of in vitro tumor proliferation assays.
  • Tumor cells are seeded on Day 0 at subconfluent densities in RPMI growth medium with 10% FBS and incubated at 37 °C in a humidified incubator containing 5% CO 2 .
  • cultures are treated with various concentrations of 6-(6-aminopyridin-3-- yl)-N 4 - ⁇ 4-[(2-methylpyridin-4-yl)oxy]phenyl ⁇ pyrimidine-2,4-diamine and Paclitaxel (0 — 10 ⁇ M, 0.1% final DMSO (dimethylsulfoxide) concentration) for 72 hours.
  • Cell viability is assessed using Alamar Blue staining per the manufacturer's protocol (Trek Diagnostic Systems, Inc., Cleveland, Ohio) or measuring the ATP content using the CellTiter-Glo Assay (Promega, Wisonsin, USA).
  • mice (Taconic Farms, Germantown, NY, USA) were used for all in vivo studies. The mice were housed and maintained within the Comparative Medicine Department at Bayer Corporation, West Haven, CT in accordance with Bayer IACUC, State, and Federal guidelines for the humane treatment and care of laboratory animals. Mice received food and water ad libitum.
  • Paclitaxel (Bristol Myers Squibb, USA) came supplied as a dry powder. It was stored at room temperature as indicated on the package insert.
  • Cremophor EL /Ethanol (50:50) (Sigma Cremophor EL Cat.# C-5135; 50Og, 95% Ethyl Alcohol), was prepared as a stock solution, wrapped with aluminum foil, and stored at room temperature. Paclitaxel was formulated at 4-fold (4X) of the highest dose in this Cremophor EL/Ethanol (50:50) solution. This 4X stock solution was prepared fresh daily. Final dosing solutions were prepared by dilution to IX with endotoxin screened distilled H 2 O (GIBCO, Cat.# 15230-147) and mixed by vortexing immediately prior to dosing.
  • Solutol HS15 /Ethanol (50:50) (BAXF Solutol HS15, 95% ethyl alcohol) was prepared as a stock solution, wrapped with aluminum foil, and stored at room temperature. Compound 1 was formulated at 5-fold (5X) of the highest dose in this Solutol/Ethanol (50:50) solution. This 5X stock solution was prepared fresh daily. Final dosing solutions were prepared by dilution to IX with 0.9% saline and mixed by vortexing immediately prior to dosing.
  • the NCI-H460 human non-small-cell lung carcinoma line was obtained from the American Type Tissue Culture Collection Repository. NCI-H460 cells were maintained and passaged in vitro using DMEM (GIBCO cat. # 11995-065: 500 mis) supplemented with 10% heat inactivated fetal bovine serum (JRH Biosciences cat.# 12106-500M), 2mM L-glutamine ( GIBCO cat. # 25030-81), 1OmM HEPES buffer (GIBCO cat # 15630-080) and penicillin-streptomycin (GIBCO cat. # 15140-122: 5 mis/ 50 mis DMEM). Cells were maintained at 37 0 C and 5% CO 2 in a Fisher Scientific 610 CO 2 incubator.
  • NCI-H460 cells were initiated by harvesting cells from an in vitro culture by adding Trypsin-EDTA (GIBCO cat#25200-056 ) for 2 minutes followed by centrifugation of the cells into a pellet and resuspension in HBSS (GIBCO cat# 14025- 092) to a final cell count of 5 x 10 7 viable cells/ml. A volume of 0.1ml of the cell suspension was injected s.c. in the right flank of each mouse. All treatment was initiated when all mice in the experiment had established tumors ranging in size from 100 to 150 mg. The general health of mice was monitored and mortality was recorded daily. Tumor dimensions and body weights were recorded two to three times a week starting with the first day of treatment. Animals were euthanized according to Bayer IACUC guidelines. The maximum tolerated dose (MTD) is defined as the highest dose that produces less than 20% lethality and/or 20% net body weight loss.
  • MTD maximum tolerated dose
  • Compound 1 was administered i.v. on a q4d x 3 schedule and paclitaxel was administered i.v on a q2d x 5 schedule. On days when both compounds were administered, compound 1 was dosed first and paclitaxel was administered 4 h later. Both agents were dosed up to their respective MTD (maximum tolerated dose). Tumor weights (mg) were calculated using the equation (/ x w 2 )/2, where / and w refer to the larger and smaller dimensions collected at each measurement. There were 10 mice per group.
  • An evaluation endpoint of three tumor mass doublings was used to evaluate the anti-tumor efficacy of the combination of these agents at their MTDs to the efficacy of the corresponding single agents as represented in Table 1.
  • the tumor growth delay produced by each individual therapy was approximately 8 days (median time to reach the evaluation endpoint in the control groups was 7 days and 15 days for both compound 1 and paclitaxel.
  • the tumor growth delay produced by the combination therapy was approximately 14 days (the time to reach the evaluation endpoint in the combination therapy group was 21 days). There was no lethality on any treatment.
  • the average tumor weight at each day of measurement (mean ⁇ standard error of the mean, SEM) for each group is summarized in Table 1.
  • the compounds according to the invention can be converted into pharmaceutical preparations as follows:
  • Composition 1 mg 6-(6-aminopyridin-3-yl)-N 4 - ⁇ 4-[(2-methylpyridin-4- yl)oxy]phenyl ⁇ pyrim ⁇ dine-2,4-diamine, 1 mg Paclitaxel, 15 g polyethylenglykol 400 and 250 g water optionally with up to 15 % Cremophor EL, and optionally up to 15% ethyl alcohol, and optionally up to 2 equivalents of a pharmaceutically suitable acid such as citric acid or hydrochloric acid.
  • a pharmaceutically suitable acid such as citric acid or hydrochloric acid.
  • Composition 1 mg 6-(6-aminopyridin-3-yl)-N 4 - ⁇ 4-[(2-methyIpyridin-4- yl)oxy]phenyl ⁇ pyrimidine-2,4-diamine, 1 mg Paclitaxel, saline solution, optionally with up to 15 % by weight of Cremophor EL, and optionally up to 15% by weight of ethyl alcohol, and optionally up to 2 equivalents of a pharmaceutically suitable acid such as citric acid or hydrochloric acid.
  • a pharmaceutically suitable acid such as citric acid or hydrochloric acid.
  • Composition 1 mg 6-(6-aminopyridin-3-yl)-N 4 - ⁇ 4-[(2-methylpyridin-4- yl)oxy]phenyl ⁇ pyrimidine-2,4-diamine, 6 mg Paclitaxel, 527 mg of purified Cremophor EL, 49.7% (v/v) dehydrated ethyl alcohol USP per mL solution, dilution with a in 0.9% Sodium Chloride Injection, USP; 5% Dextrose Injection, USP; 5% Dextrose and 0.9% Sodium Chloride Injection, USP, or 5% Dextrose in Ringer's Injection.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une nouvelle combinaison de composés de paclitaxel et des procédés pour sa préparation. Elle concerne également des procédés de traitement de maladies, en particulier le cancer, permettant l'administration de ladite combinaison, et des procédés de fabrication de ladite composition pharmaceutique pour le traitement ou la prévention de troubles, en particulier du cancer.
PCT/US2007/006920 2006-03-20 2007-03-20 Combinaison de paclitaxel Ceased WO2007109275A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002646971A CA2646971A1 (fr) 2006-03-20 2007-03-20 Combinaison de paclitaxel
EP07753541A EP2001477A4 (fr) 2006-03-20 2007-03-20 Combinaison de paclitaxel
JP2009501514A JP2009530386A (ja) 2006-03-20 2007-03-20 パクリタキセル組み合わせ物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78495406P 2006-03-20 2006-03-20
US60/784,954 2006-03-20

Publications (2)

Publication Number Publication Date
WO2007109275A2 true WO2007109275A2 (fr) 2007-09-27
WO2007109275A3 WO2007109275A3 (fr) 2009-04-02

Family

ID=38523056

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/006920 Ceased WO2007109275A2 (fr) 2006-03-20 2007-03-20 Combinaison de paclitaxel

Country Status (4)

Country Link
EP (1) EP2001477A4 (fr)
JP (1) JP2009530386A (fr)
CA (1) CA2646971A1 (fr)
WO (1) WO2007109275A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007076260A2 (fr) 2005-12-19 2007-07-05 Smithkline Beecham Corporation Agonistes de recepteur de farnesoide x

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924290B2 (en) * 2002-01-23 2005-08-02 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
EP1689722A2 (fr) * 2003-10-10 2006-08-16 Bayer Pharmaceuticals Corporation Derives de pyrimidine dans le traitement de troubles hyperproliferatifs
WO2006099231A1 (fr) * 2005-03-10 2006-09-21 Bayer Pharmaceuticals Corporation Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP2001477A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007076260A2 (fr) 2005-12-19 2007-07-05 Smithkline Beecham Corporation Agonistes de recepteur de farnesoide x

Also Published As

Publication number Publication date
WO2007109275A3 (fr) 2009-04-02
JP2009530386A (ja) 2009-08-27
EP2001477A4 (fr) 2010-07-21
EP2001477A2 (fr) 2008-12-17
CA2646971A1 (fr) 2007-09-27

Similar Documents

Publication Publication Date Title
KR101716804B1 (ko) 항종양 알칼로이드를 이용한 병용요법
EP3042669B1 (fr) Agent antitumoral et promoteur de l'effet antitumoral
KR101922096B1 (ko) Ｈｋｉ-272 및 비노렐빈을 함유하는 항신생물성 조합물
EP3053578B1 (fr) Polythérapie contre le cancer utilisant un composé azabicyclo
WO2010138377A1 (fr) Compositions et procédés de traitement du cancer
TW202131926A (zh) 包含alk2抑制劑及jak2抑制劑的組合療法
EP2920187A1 (fr) Procédé d'utilisation de composés binucléaires à base d'or(i) pour le traitement d'un cancer
CN109498627B (zh) 一种治疗肿瘤的药物组合物及其应用
WO2015172712A1 (fr) Composition pharmaceutique pour injection avec effet synergique de la vitamine c et des médicaments antitumoraux
EP2001477A2 (fr) Combinaison de paclitaxel
AU2012235902B2 (en) Therapeutic treatment
CN106822099A (zh) 维生素c与苯磺酰胺化合物协同作用的注射用药物组合物
EP2826482A1 (fr) Nouvel agent antitumoral comprenant une association de trois agents
EP3127544B1 (fr) Médicament antitumoral contenant un complexe de platine antitumoral et promoteur de l'effet antitumoral
CN111773388B (zh) A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用
KR20220156597A (ko) 부틸프탈라이드 및 이의 유도체의 용도
CN107921134B (zh) 肿瘤基因甲基化调节剂的新用途及抗肿瘤药物
JP6488280B2 (ja) タキサン系化合物を含有する抗腫瘍剤及び抗腫瘍効果増強剤
CN111558045A (zh) 一种治疗肺癌的药物组合物
CN103772374A (zh) 一种新型杂环类化合物及其应用
CN114945364A (zh) 用于癌症治疗的组合及其应用
CN104116729A (zh) 氟代紫杉烷类衍生物在制备治疗结肠癌药物中的用途
JP2014040401A (ja) 肝細胞癌治療剤
CN107737127A (zh) 一种氯喹和靶向共输送纳米复合物的组合物的应用
AU2013202963A1 (en) Antineoplastic Combinations Containing HKI-272 and Vinorelbine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07753541

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009501514

Country of ref document: JP

Ref document number: 2646971

Country of ref document: CA

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007753541

Country of ref document: EP